跳至主要内容
临床试验/NCT02029898
NCT02029898已完成1 期

Adaptation to Neonatal Life After an Anesthetic Protocol Using Remifentanil for General Anesthesia for Caesarean Section in a Context of Prematurity - REAGI Protocol

University Hospital, Rouen1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2014年2月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
53
试验地点
1
主要终点
Apgar Score value below 7 after 5 minutes

研究概览

简要总结

One of the problems during general anesthesia (GA) for caesarean section is the place of opioid agents. Indeed, the literature does not provide so far a clear answer regarding the use of opioids prior to extraction of the newborn. Indeed, if the opioid administration at induction is beneficial for the mother (better control of autonomic responses to noxious stimuli), the impact on the newborn can be unfavorable in terms of adaptation to extrauterine life . This is especially true if the birth takes place in a context of prematurity and / or acute fetal distress.

The pharmacokinetics of remifentanil make it the only opioid which is consistent with a rapid sequence induction. Its short period of action avoids the manual ventilation of patients before intubation, while providing a peak of action concomitant to the nociceptive stimulation. Patients at high risk of aspiration, including pregnant women, may benefit from this type of morphine at induction. In addition, the fact that remifentanil seems to be associated with relative fetal safety in obstetrical or neonatal context legitimized the development of protocols to study maternal-fetal consequences of the use of remifentanil at induction of AG for emergency caesarean section.

While cesarean section under general anesthesia mainly concern premature newborns in France, no work has focused on the use of remifentanil for caesarean section in a context of preterm without preeclampsia.

The main hypothesis of this study is to evaluate the safety of the use of remifentanil in terms of adaptation to extrauterine life in children born prematurely by caesarean section under general anesthesia outside the context of preeclampsia.

To do this, we will compare two groups of children, one consisting of children born by cesarean section under general anesthesia with maternal remifentanil infusion, the other made up of children born by cesarean section under general anesthesia without maternal infusion of remifentanil. This study is prospective, single-center, randomized, double-blinded.

The primary endpoint is formed by the value of the Apgar score less than 7 at 5 minutes, calculated in the delivery room by the team supporting the child (midwives and pediatricians).

The secondary endpoints are formed by maternal hemodynamic parameters (SBP, DBP, MAP, HR), the rate of complications during induction (difficult intubation, aspiration), the onset of respiratory distress requiring ventilation mask in the newborn, the rate of intubation in neonates, and the rate of use of adjuvant anesthetic agents.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Inclusion criteria of the mother:
  • Patient over 18 years
  • Single pregnancy with an indication for cesarean section under general anesthesia context of prematurity (<37SA)
  • Patient informed and written consent for participation in this research signed
  • Affiliation to social security
  • Inclusion criteria of the child:
  • Parents informed and written consent signed by the father and mother for the participation in this research by the child (unless a parent no longer has parental authority)

排除标准

  • Non-inclusion criteria of the mother:
  • Vaginal Delivery
  • Mother pathology requiring the use of an opioid during induction
  • Severe Preeclampsia
  • More than 14 weeks between the information and the inclusion
  • Patient under guardianship
  • Non-inclusion criteria of the child:
  • Fetal pathology diagnosed in the prenatal period involving the prognosis of the child

研究组 & 干预措施

Remifentanil

Active Comparator

injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute

干预措施: Remifentanil (Drug)

Placebo

Placebo Comparator

injectable solution 0.9% for the end of surgery

干预措施: sodium chloride 0,9% (Drug)

结局指标

主要结局

Apgar Score value below 7 after 5 minutes

时间窗: 5 minutes afer birth

Apgar Score value below 7 after 5 minutes calculated in the delivery room by the team supporting the child (midwives or pediatric)

次要结局

  • Rate of complications of induction (difficult intubation, inhalation)(intraoperative)
  • Intubation rate among newborns(intraoperative)
  • Occurrence of respiratory distress requiring mask ventilation of the newborn(intraoperative)
  • Rate of the use of adjuvant anesthetic agents(intraoperative)
  • Maternal hemodynamic parameters (SBP, DBP, MAP, HR),(intraoperative)
  • Umbilical cordon blood pH(intraoperative)

研究者

发起方
University Hospital, Rouen
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Remifentanil for General Anesthesia in the Context... | 临床试验